Mirati Therapeutics, Inc. (MRTX) News Headlines

▮ More

Date

Headline

11/28/2022 12:38:51 AM Biotech Stocks Facing FDA Decision In December 2022

10/12/2022 8:29:28 AM Mirati, Aadi To Evaluate Adagrasib, Nab-sirolimus Combination To Treat NSCLC, Other Solid Tumors

10/12/2022 8:08:41 AM Mirati, Aadi To Evaluate Adagrasib - Nab-sirolimus Combination In Advanced NSCLC And Other Solid Tumors

8/31/2022 10:33:59 AM Mirati Therapeutics Stock Gains 6%

8/4/2022 5:25:05 AM VNDA On Watch, NUVA Q2 Results Miss Estimates, MRTX Awaits FDA Decision...

7/22/2022 6:43:49 AM Pre-market Movers: NCPL, SNAP, HNGR, PDSB, IPI…

6/7/2022 9:50:48 AM Mirati Therapeutics Jumps 20% On Positive Study Results Of Adagrasib For NSCLC

5/27/2022 10:50:34 AM Mirati Therapeutics Falls 34%

5/27/2022 7:44:40 AM Pre-market Movers: IOVA, MRTX, BIG, GPS, PMVP…

3/11/2022 7:53:41 AM Pre-market Movers: EXN, ONE, TLYS, IMVT, LAZY…

1/21/2022 10:02:01 AM Mirati Presents Positive Data With Investigational Adagrasib In Patients With KRASG12C-Mutated Gastrointestinal Cancers

11/22/2021 7:49:54 AM Mirati, Verastem To Evaluate Adagrasib, VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer

11/22/2021 7:41:07 AM Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer

11/22/2021 7:30:00 AM Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer (Press Release)

11/17/2021 7:33:06 AM Mirati Therapeutics Submits INDA To U.S. FDA Of MRTX1719 To Treat MTAP-Deleted Cancers

11/17/2021 7:30:00 AM Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers (Press Release)

11/10/2021 10:08:11 PM Mirati Therapeutics Prices Underwritten Public Offering Of 3.45 Mln Shares At $145.00/shr

9/20/2021 8:37:59 AM Mirati Reports Positive Topline Data From Phase 2 Study With Adagrasib; Names David Meek CEO

9/20/2021 8:25:32 AM Mirati Therapeutics Announces Long-term Survival Results From Exploratory Analysis Of Sitravatinib Plus Nivolumab

9/20/2021 8:04:41 AM Mirati Therapeutics Appoints David Meek As CEO